Hollis-Eden

James M. Frincke, Ph.D. has been named president and chief executive officer of Hollis-Eden Pharmaceuticals, Inc. Dr. Frincke was also elected to the company’s board of directors.

Dr. Frincke joined Hollis-Eden in 1997 as vice president, R&D, was promoted to executive vice president in 1999, and to chief scientific officer in 2001. He joined Hollis-Eden from Prolinx, Inc., where he served as vice president, Therapeutics R&D, from 1995 to 1997. During his 28 years in the biotechnology industry, Dr. Frincke has managed major development programs including drugs, biologicals, and cellular and gene therapy products aimed at the treatment of cancer, infectious diseases and organ transplantation.

Dr. Frincke has held vice president, R&D positions in top-tier biotechnology companies including Hybritech/Eli Lilly and SyStemix Inc. (acquired by Novartis). In various capacities, he has been responsible for all aspects of pharmaceutical development including early stage research programs, product evaluation, pharmacology, manufacturing, and the management of regulatory and clinical matters for lead product opportunities.